According to Quest Diagnostics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.56157. At the end of 2023 the company had a P/S ratio of 1.64.
Year | P/S ratio | Change |
---|---|---|
2023 | 1.64 | -9.02% |
2022 | 1.80 | -8.37% |
2021 | 1.97 | 15.6% |
2020 | 1.70 | -7.43% |
2019 | 1.84 | 23.16% |
2018 | 1.49 | -14.28% |
2017 | 1.74 | 2.71% |
2016 | 1.70 | 24.88% |
2015 | 1.36 | 4.53% |
2014 | 1.30 | 20.37% |
2013 | 1.08 | -12.66% |
2012 | 1.24 | 1.29% |
2011 | 1.22 | -2.46% |
2010 | 1.25 | -15.77% |
2009 | 1.48 | 5.98% |
2008 | 1.40 | -8.56% |
2007 | 1.53 | -6.53% |
2006 | 1.64 | -11.71% |
2005 | 1.86 | -1.58% |
2004 | 1.89 | 18.89% |
2003 | 1.59 | 16.92% |
2002 | 1.36 | -28.51% |
2001 | 1.90 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() LabCorp LH | 1.27 | -18.51% | ๐บ๐ธ USA |
![]() Translate Bio
TBIO.defunct | N/A | N/A | ๐บ๐ธ USA |
![]() Psychemedics PMD | 1.10 | -29.31% | ๐บ๐ธ USA |
![]() NeoGenomics
NEO | 4.10 | 162.47% | ๐บ๐ธ USA |
![]() Qiagen QGEN | 5.17 | 230.93% | ๐ณ๐ฑ Netherlands |
![]() Enzo Biochem ENZ | 1.40 | -10.50% | ๐บ๐ธ USA |